Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Quadrivalent Influenza Vaccine in People Aged 3 Years and Above
NCT06622590Phase 1Active, not recruiting
- Sponsor
- Institute of Medical Biology
- Start
- Oct 2024
- Primary completion
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of influenza virus vaccine, quadrivalent, split virion in influenza (9 arms), sponsored by Institute of Medical Biology. Primary endpoint: Incidence of adverse events/adverse reactions at 30 days. Started Oct 2024; status: active, not recruiting.
02
Drugs
influenza virus vaccine, quadrivalent, split virion
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06622590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06622590.